The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Hypertrophic obstructive cardiomyopathy (HOCM) patients often develop disabling symptoms of
heart failure. Current treatment strategies are predicated on the empirical use of
long-standing drugs, such as beta-adrenergics, although with little evidence supporting their
clinical beneļ¬t in this disease. Metoprolol is currently the most widely used beta-blocker in
symptomatic HOCM patients, but a randomized, placebo-controlled trial, that looks at the
effect in HOCM patients has never been conducted. No studies of HOCM combine invasive
pressure measurement with exercise and echocardiography. All previous studies, both invasive
and echocardiographic, have been conducted during rest, and not during exercise. Symptoms of
HOCM patients are function-related, and exercise testing is essential to assess the condition
and the effect of drugs.